GENMAB A/S's ticker is GMAB and the CUSIP is 372303206. A total of 2 filers reported holding GENMAB A/S in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $0 | – | 10 | 0.0% | 0.00% | – |
| Q2 2023 | $0 | – | 10 | +100.0% | 0.00% | – |
| Q1 2023 | $0 | -100.0% | 5 | -100.0% | 0.00% | -100.0% |
| Q4 2022 | $1,657 | -99.9% | 39,105 | +0.3% | 0.00% | 0.0% |
| Q3 2022 | $1,253,000 | – | 39,005 | +780000.0% | 0.00% | – |
| Q2 2022 | $0 | -100.0% | 5 | -90.2% | 0.00% | – |
| Q1 2022 | $2,000 | -99.5% | 51 | -99.5% | 0.00% | – |
| Q3 2021 | $422,000 | +7.7% | 9,650 | +0.6% | 0.00% | – |
| Q2 2021 | $392,000 | +4800.0% | 9,592 | +3691.3% | 0.00% | – |
| Q1 2021 | $8,000 | +300.0% | 253 | +450.0% | 0.00% | – |
| Q4 2020 | $2,000 | 0.0% | 46 | 0.0% | 0.00% | – |
| Q3 2020 | $2,000 | 0.0% | 46 | 0.0% | 0.00% | – |
| Q2 2020 | $2,000 | -33.3% | 46 | -62.0% | 0.00% | – |
| Q4 2019 | $3,000 | -96.4% | 121 | -97.1% | 0.00% | – |
| Q3 2019 | $84,000 | – | 4,183 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aquilo Capital Management, LLC | 52,148 | $1,839,260 | 1.67% |
| Ativo Capital Management LLC | 28,442 | $1,003,132 | 1.13% |
| HARDING LOEVNER LP | 3,204,230 | $113,013,183 | 0.75% |
| Hardman Johnston Global Advisors LLC | 592,318 | $20,891,056 | 0.70% |
| Yorktown Management & Research Co Inc | 16,600 | $585,482 | 0.66% |
| TORRAY INVESTMENT PARTNERS LLC | 104,516 | $3,686,279 | 0.65% |
| First Light Asset Management, LLC | 157,147 | $5,542,575 | 0.53% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 44,300 | $1,561,575 | 0.53% |
| Capricorn Fund Managers Ltd | 37,007 | $1,305,237 | 0.45% |
| Legacy Wealth Asset Management, LLC | 29,496 | $1,040,324 | 0.38% |